DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The "Achondroplasia - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Achondroplasia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Achondroplasia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Achondroplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 2 respectively.

This pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Ascendis Pharma A/S BioClin Therapeutics Inc. BioMarin Pharmaceutical Inc. Ribomic Inc.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Achondroplasia - Overview

4. Achondroplasia - Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Products under Development by Companies

8. Achondroplasia - Therapeutics Assessment

9. Assessment by Target

10. Assessment by Mechanism of Action

11. Assessment by Route of Administration

12. Assessment by Molecule Type

13. Achondroplasia - Companies Involved in Therapeutics Development

14. Ascendis Pharma A/S

15. BioClin Therapeutics Inc.

16. BioMarin Pharmaceutical Inc.

17. Ribomic Inc.

18. Achondroplasia - Drug Profiles

19. ACP-015 - Drug Profile

20. B-701 - Drug Profile

21. infigratinib - Drug Profile

22. RBM-007 - Drug Profile

23. TA-46 - Drug Profile

24. vosoritide - Drug Profile

25. Achondroplasia - Dormant Projects

26. Achondroplasia - Product Development Milestones

Featured News & Press Releases

Therachon Announces Start of Natural History Study in Children with Achondroplasia BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia Ascendis Pharma Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia Ascendis Pharma Provides Update on TransCon CNP Ascendis Pharma Announces Presentations on TransCon CNP at Upcoming Medical Conferences Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia Ascendis Pharma Presents Data on TransCon CNP at ENDO 2 Ascendis Pharma Announces Data on TransCon CNP at ENDO 2 BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics 2016 Meeting BioMarin Provides Program Update on Vosoritide in Achondroplasia BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting BMN 111 Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9xhx4v/achondroplasia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180913006036/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Musculoskeletal Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/13/2018 03:56 PM/DISC: 09/13/2018 03:56 PM